Royalty Pharma (RPD) Price & Analysis

5 Followers

RPD Stock Chart & Stats

€51.31

-€1.67(-3.15%)

At close: Jul 30 4:00 PM EDT

€51.31

-€1.67(-3.15%)

Day’s Range― - ―

52-Week Range€28.87 - €52.98

Previous CloseN/A

Volume69.00

Average Volume (3M)30.00

Market Cap

€28.84B

Enterprise Value€42.30K

Total Cash (Recent Filing)€836.99M

Total Debt (Recent Filing)€8.96B

Price to Earnings (P/E)24.6

Beta0.27

Next Earnings

Nov 11, 2026

EPS Estimate

1.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)2.41

Shares Outstanding445,277,340

10 Day Avg. Volume2

30 Day Avg. Volume30

Financial Highlights & Ratios

PEG Ratio0.78

Price to Book (P/B)2.58

Price to Sales (P/S)7.02

P/FCF Ratio6.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€56.88

Price Target Upside10.85% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)4.6

Revenue Forecast (FY)€3.02B

Bulls Say, Bears Say

Bulls Say

Very Strong Cash Generation And ConversionRoyalty Pharma’s operating cash flow and free cash flow are large and growing, with operating cash well above net income and ~95% cash conversion. This durable cash generation supports debt servicing, repeat acquisitions, and shareholder returns, underpinning capital allocation flexibility over years.

Expanded Development Pipeline And Strategic Cliramitug DealRoyalty Pharma’s move into late‑stage development with a larger, diversified pipeline (now 19 assets) plus the cliramitug royalty creates future high‑leverage payoffs if trials succeed. A broader deal flow reduces single‑asset concentration and supports multi‑year royalty receipt growth when approvals occur.

Improved Liquidity And Credit ProfileA new $1.8B revolver plus an investment‑grade upgrade enhance structural liquidity and funding optionality for acquisitions. Better access to committed capital and improved credit standing lowers refinancing risk and supports disciplined, long‑term capital deployment into royalty investments.

Bears Say

Material And Rising LeverageRoyalty Pharma’s meaningful debt load and upward leverage trend reduce financial flexibility if portfolio receipts falter. High absolute debt requires sustained cash conversion to meet interest and covenant tests, increasing vulnerability to cyclical or product‑specific revenue disruptions over a multi‑quarter horizon.

Dependence On Late‑stage Clinical OutcomesA growing portion of prospective returns is tied to development‑stage assets that require successful pivotal trials. If late‑stage readouts are delayed or fail, expected future royalty streams and projected IRRs could be materially reduced, making near‑term growth contingent on binary clinical outcomes.

One‑time Milestone Declines And Structural Product HeadwindsExpected drops in milestone receipts and identifiable product pressures (loss of exclusivity, biosimilar entry, policy changes) create persistent revenue risk for certain portfolio components. These structural headwinds complicate predictability of receipts and require more acquisitions or organic growth to sustain long‑term revenue trends.

Royalty Pharma News

3 ‘Perfect Ten’ Healthcare Stocks That Analysts Rate as a Strong Buy

We are diving into three healthcare stocks which all have a Strong Buy consensus and a 10 out...

3d ago

GMAB

RPRX

Royalty Pharma price target raised to $66 from $59 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Royalty Pharma (RPRX) to $66 from $59 and keeps a...

7d ago

RPRX

Royalty Pharma price target raised to $65 from $64 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Royalty Pharma (RPRX) to $65 from $64 and keeps an...

7d ago

RPRX

Royalty Pharma price target raised to $70 from $66 at Citi

Citi raised the firm’s price target on Royalty Pharma (RPRX) to $70 from $66 and keeps a Buy...

7d ago

RPRX

Royalty Pharma reports Q2 revenue $647M, consensus $758.88M

“Royalty Pharma (RPRX) delivered strong second quarter results with Royalty Receipts growth of 14%,” said Pablo Legorreta, Royalty...

8d ago

RPRX

Royalty Pharma buys royalty interest in AstraZeneca cliramitug for $125M upfront

Royalty Pharma (RPRX) announced that it has acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s (AZN) cliramitug...

22d ago

AZN

RPRX

Royalty Pharma lifts 2026 outlook amid strong cash flows

Royalty Pharma PLC (($RPRX)) has held its Q2 earnings call. Read on for the main highlights of the...

2d ago

RPRX

Royalty Pharma price target raised to $65 from $50 at TD Cowen

TD Cowen raised the firm’s price target on Royalty Pharma (RPRX) to $65 from $50 and keeps a...

1M ago

RPRX

Royalty Pharma Shareholders Back Board, Pay and Flexibility

Royalty Pharma ( ($RPRX) ) has provided an announcement. On June 4, 2026, Royalty Pharma held its 2026...

2M ago

RPRX

Royalty Pharma Secures New $1.8 Billion Credit Facility

Royalty Pharma ( ($RPRX) ) has shared an announcement. On May 22, 2026, Royalty Pharma plc entered into...

3M ago

RPRX

Royalty Pharma price target raised to $64 from $63 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Royalty Pharma (RPRX) to $64 from $63 and keeps an...

3M ago

RPRX

Royalty Pharma price target raised to $58 from $50 at JPMorgan

JPMorgan raised the firm’s price target on Royalty Pharma (RPRX) to $58 from $50 and keeps an Overweight...

3M ago

RPRX

Royalty Pharma price target raised to $66 from $50 at Citi

Citi analyst Geoff Meacham raised the firm’s price target on Royalty Pharma (RPRX) to $66 from $50 and...

3M ago

RPRX

Royalty Pharma’s Earnings Call Signals Confident Growth

Royalty Pharma PLC (($RPRX)) has held its Q1 earnings call. Read on for the main highlights of the...

3M ago

RPRX

RPD FAQ

What was Royalty Pharma PLC’s price range in the past 12 months?

Royalty Pharma PLC lowest stock price was €28.87 and its highest was €52.98 in the past 12 months.

What is Royalty Pharma PLC’s market cap?

Royalty Pharma PLC’s market cap is €28.84B.

When is Royalty Pharma PLC’s upcoming earnings report date?

Royalty Pharma PLC’s upcoming earnings report date is Nov 11, 2026 which is in 90 days.

How were Royalty Pharma PLC’s earnings last quarter?

Royalty Pharma PLC released its earnings results on Aug 05, 2026. The company reported €1.144 earnings per share for the quarter, beating the consensus estimate of €1.103 by €0.042.

Is Royalty Pharma PLC overvalued?

According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Royalty Pharma PLC pay dividends?

Royalty Pharma PLC does not currently pay dividends.

What is Royalty Pharma PLC’s EPS estimate?

Royalty Pharma PLC’s EPS estimate is 1.01.

How many shares outstanding does Royalty Pharma PLC have?

Royalty Pharma PLC has 445,277,340 shares outstanding.

What happened to Royalty Pharma PLC’s price movement after its last earnings report?

Royalty Pharma PLC reported an EPS of €1.144 in its last earnings report, beating expectations of €1.103. Following the earnings report the stock price went up 3.739%.

Which hedge fund is a major shareholder of Royalty Pharma PLC?

Currently, no hedge funds are holding shares in DE:RPD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Royalty Pharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

1.55%

Trailing 12-Months

Asset Growth

12.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Royalty Pharma PLC

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma (RPD) Earnings & Revenues

Historic Earnings Reports

RPD Company Deck

RPD Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call emphasized multiple strong positives: double‑digit recurring cash flow growth, raised full‑year guidance, disciplined capital deployment (including a strategic cliramitug purchase), expanded development‑stage pipeline with high historical success rates, robust cash generation, and an investment‑grade credit upgrade. Lowlights were present but largely manageable: a material decline in milestone/contract receipts (one‑time prior period effect), specific product headwinds (Promacta, biosimilar Tysabri, IRA), dependence on future pivotal trial outcomes for some investments, modestly higher expected operating expense rates in H2, and geopolitical/regulatory uncertainty in China. Overall, the positives—strong growth, improved guidance, financial flexibility, and portfolio expansion—substantially outweigh the risks and near‑term headwinds.View all DE:RPD earnings summaries

RPD Revenue Breakdown

93.34% Income from financial royalty assets

6.62% Other royalty income

0.04% Revenue from intangible royalty assets

RPD Stock 12 Month Forecast

Average Price Target

€56.88

▲(10.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"€28","61":"€61","36.25":"€36.3","44.5":"€44.5","52.75":"€52.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60.6284224,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€60.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.87523434666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€56.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53.69945984,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€53.70</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,36.25,44.5,52.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.99,51.73141710769231,52.472834215384616,53.21425132307692,53.95566843076923,54.697085538461536,55.43850264615385,56.17991975384615,56.921336861538464,57.66275396923077,58.40417107692308,59.145588184615384,59.88700529230769,{"y":60.6284224,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.99,51.44271033435898,51.895420668717954,52.34813100307693,52.8008413374359,53.253551671794874,53.70626200615385,54.158972340512825,54.6116826748718,55.06439300923078,55.51710334358975,55.96981367794872,56.4225240123077,{"y":56.87523434666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.99,51.19841998769231,51.40683997538462,51.61525996307692,51.82367995076923,52.03209993846154,52.24051992615385,52.448939913846154,52.65735990153846,52.86577988923077,53.07419987692308,53.282619864615384,53.49103985230769,{"y":53.69945984,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.755,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.961,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.636,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.211,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.201,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.508,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.043,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.596,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.328,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.453,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.52,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.775,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.99,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >